AnaCipher Clinical Research Organization

AnaCipher (CRO) BABE Centre holds approvals from the world’s leading regulatory authorities, including the USFDA, EMA, NPRA, WHO, UKMHRA and GCC (MOH - OMAN), in addition to local regulatory authority. Our Centre has successfully undergone seven FDA inspections without receiving any 483 observations, underscoring our commitment to the highest standards of quality and compliance. In 2023, we were inspected by EMA - Denmark & Finland, and in 2024 by WHO, both resulting in issuance of inspection closure letters. Recently March 2025, successfully completed USFDA inspection as well.

Our key capabilities include:

146-bed facility: Split into four independent Clinical Pharmacology Units (CPUs) for flexible and efficient study execution. Advanced Analytical Facilities: Equipped with 8 LC-MS/MS systems to support complex analytical requirements. Validated Methods – 250+ NABL...